Neobe raised USD 6.8 million, also reported as GBP 5 million, in seed funding led by ARC Ventures. Faber, Macmillan Ventures, Proven Connect, Empirical Ventures and 2048 Ventures also participated. The London biotechnology company engineers bacteria intended to break down physical barriers around solid tumours that can prevent treatments from reaching cancer cells. The capital will support development of its lead programme, NEO22, toward a planned regulatory filing in 2028 and strengthen the team. The technology remains preclinical, and no approved treatment or completed human clinical result was announced.
Neobe raises USD 6.8m for engineered cancer-treatment bacteria
ARC Ventures leads the seed round.

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


